Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma.
Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma.
复制标题
黑色素瘤患者血清中黑色素瘤相关抗原 CYT-MAA 和 HMW-MAA 的存在及其预后意义。
DOI：
10.1111/j.0022-202x.2005.23798.x
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
Reynolds,SandraR
中科院分区：
文献类型：
--
作者：
Vergilis,IreneJ;Szarek,Michael;Ferrone,Soldano;Reynolds,SandraR
为了寻找血清学标志物来监测早期和晚期黑色素瘤患者，我们比较了黑色素瘤患者和对照组血清中细胞质黑色素瘤相关抗原（CYT-MAA）和高分子量黑色素瘤相关抗原（HMW-MAA）的水平。使用双夹心ELISA，我们测量了117例患者和62名年龄和性别匹配的对照组的两种抗原水平。根据疾病的分期，将患者分为四个风险组。两种标记物的血清水平在黑素瘤患者中显著高于对照组。CYT-MAA是更敏感的标志物，61%的患者无论疾病分期均显示升高水平。HMW-MAA升高29%。升高的CYT-MAA也与较差的临床结局显著相关。通过多变量分析（根据分期和年龄调整），CYT-MAA升高的患者复发的可能性比检测不到水平的患者高81%（风险比=1.81，95% CI=[1.07，3.06]，p值=0.03）。HMW-MAA水平升高与预后不良无关。这些结果表明，CYT-MAA和HMW-MAA都是切除疾病患者中残留黑色素瘤的血清标志物。此外，CYT-MAA似乎是黑色素瘤疫苗治疗患者临床结果的预后标志物。
With the goal of finding serological markers to monitor patients with early- as well as late-stage melanoma, we compared the levels of the cytoplasmic melanoma-associated antigens (CYT-MAA) and high-molecular-weight melanoma-associated antigen (HMW-MAA) in the sera of melanoma patients and controls. Using double-sandwich ELISA, we measured levels of both antigens in 117 patients and in 62 age- and sex-matched controls. Patients were stratified into four risk group based on stage of the disease. Serum levels of both markers were significantly higher in melanoma patients than in controls. CYT-MAA was the more sensitive marker, with 61% of patients showing elevated levels regardless of the stage of disease. HMW-MAA was elevated in 29%. Elevated CYT-MAA was also significantly correlated with poorer clinical outcome. By multivariate analysis (adjusting for stage and age), patients who had elevated CYT-MAA were 81% more likely to recur than patients with undetectable levels (hazard ratio=1.81, 95% CI=[1.07, 3.06], p-value=0.03). Elevated levels of HMW-MAA did not correlate with poor prognosis. These results suggest that both CYT-MAA and HMW-MAA are serum markers for residual melanoma in patients with resected disease. Furthermore, CYT-MAA appears to be a prognostic marker of clinical outcome in melanoma vaccine-treated patients.